
Merrilee Needham, Mbbs, Fracp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/761390/publications.pdf Version: 2024-02-01



Merrilee Needham, Mbbs,

#	Article	IF	CITATIONS
1	Polygenic risk score analysis for amyotrophic lateral sclerosis leveraging cognitive performance, educational attainment and schizophrenia. European Journal of Human Genetics, 2022, 30, 532-539.	2.8	16
2	Evaluation of an Australian neurological nurseâ€led model of postdischarge care. Health and Social Care in the Community, 2022, 30, .	1.6	5
3	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 321-328.	1.7	4
4	Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations. Internal Medicine Journal, 2022, 52, 110-120.	0.8	3
5	Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1. Genome Medicine, 2022, 14, 7.	8.2	12
6	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38
7	Expanding the MYOD1 phenotype: A case report of a patient diagnosed whilst pregnant. Journal of Neuromuscular Diseases, 2022, , 1-4.	2.6	0
8	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299.	1.7	42
9	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	8.8	49
10	Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype. Frontiers in Aging Neuroscience, 2021, 13, 658226.	3.4	38
11	Idiopathic inflammatory myopathies: a review. Internal Medicine Journal, 2021, 51, 845-852.	0.8	28
12	Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. Annals of Clinical and Translational Neurology, 2021, 8, 1991-1999.	3.7	18
13	Isolation of Live Leukocytes from Human Inflammatory Muscles. Methods and Protocols, 2021, 4, 75.	2.0	2
14	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
15	Exploring the efficacy of the expiratory muscle strength trainer to improve swallowing in inclusion body myositis: A pilot study. Neuromuscular Disorders, 2020, 30, 294-300.	0.6	8
16	Attitudes Toward Noninterventional Observational Studies in US and Australian Patients With Sporadic Inclusion Body Myositis. Journal of Clinical Neuromuscular Disease, 2020, 21, 246-247.	0.7	1
17	Assessing the content validity of patient-reported outcome measures in adult myositis: A report from the OMERACT myositis working group. Seminars in Arthritis and Rheumatism, 2020, 50, 943-948.	3.4	6
18	Is it Pompe Disease? Australian diagnostic considerations. Neuromuscular Disorders, 2020, 30, 389-399.	0.6	4

#	Article	IF	CITATIONS
19	Investigation of hereditary muscle disorders in the genomic era. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2020, 19, 17-20.	0.1	0
20	Acute spontaneous spinal cord infarction: Utilisation of hyperbaric oxygen treatment, cerebrospinal fluid drainage and pentoxifylline. Diving and Hyperbaric Medicine, 2020, 50, 325-331.	0.5	2
21	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	10.2	91
22	Imaging in the diagnosis of idiopathic inflammatory myopathies; indications and utility. Expert Review of Neurotherapeutics, 2019, 19, 173-184.	2.8	7
23	078â€Sensory nerve abnormalities in motor neuron disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A25.1-A25.	1.9	0
24	<p>Dysphagia in Patients with Sporadic Inclusion Body Myositis: Management Challenges</p> . International Journal of General Medicine, 2019, Volume 12, 465-474.	1.8	22
25	Clinical Utility Gene Card for: Becker muscular dystrophy. European Journal of Human Genetics, 2018, 26, 1065-1071.	2.8	2
26	Primary lateral sclerosis-like picture in a patient with a remote history of anti-N-methyl-D- aspartate receptor (anti-NMDAR) antibody encephalitis. BMJ Case Reports, 2018, 2018, bcr-2017-224060.	0.5	1
27	Clinical Utility Gene Card for: autosomal dominant myotonia congenita (Thomsen Disease). European Journal of Human Genetics, 2018, 26, 1072-1077.	2.8	1
28	Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects. Expert Opinion on Orphan Drugs, 2017, 5, 431-443.	0.8	3
29	A Systematic Review and Meta-Analysis ofÂPrevalence Studies of Sporadic Inclusion Body Myositis. Journal of Neuromuscular Diseases, 2017, 4, 127-137.	2.6	49
30	Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. Journal of Neuromuscular Diseases, 2016, 3, 67-75.	2.6	44
31	Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open, 2016, 6, e012054.	1.9	48
32	Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective. Neuromuscular Disorders, 2016, 26, 734-740.	0.6	32
33	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. Neurobiology of Aging, 2016, 47, 218.e1-218.e9.	3.1	40
34	Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clinical Neurophysiology, 2016, 127, 1764-1773.	1.5	59
35	Prominent scapulae mimicking an inherited myopathy expands the phenotype of CHD7-related disease. European Journal of Human Genetics, 2016, 24, 1216-1219.	2.8	2
36	Immunotherapies for Immune-Mediated Myopathies: A Current Perspective. Neurotherapeutics, 2016, 13, 132-146.	4.4	11

Merrilee Needham, Mbbs,

#	Article	IF	CITATIONS
37	Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. Journal of Clinical Neuroscience, 2015, 22, 6-13.	1.5	40
38	Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis. Neuromuscular Disorders, 2014, 24, 1036-1041.	0.6	29
39	Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology, 2014, 83, 426-433.	1.1	192
40	Necrotizing autoimmune myopathy. Current Opinion in Rheumatology, 2011, 23, 612-619.	4.3	118
41	Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. Journal of Clinical Neuroscience, 2008, 15, 1350-1353.	1.5	126
42	Apolipoprotein ε alleles in sporadic inclusion body myositis: A reappraisal. Neuromuscular Disorders, 2008, 18, 150-152.	0.6	15
43	Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscular Disorders, 2007, 17, 194-200.	0.6	217
44	Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurology, The, 2007, 6, 620-631.	10.2	239